{"id":20354,"date":"2022-07-04T15:33:56","date_gmt":"2022-07-04T13:33:56","guid":{"rendered":"https:\/\/www.izb-online.de\/20344\/"},"modified":"2022-07-04T15:42:51","modified_gmt":"2022-07-04T13:42:51","slug":"20344","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/sirana-pharma-collaborates-with-pfizer-to-investigate-a-novel-treatment-for-a-rare-bone-disease\/","title":{"rendered":"Sirana Pharma collaborates with Pfizer to investigate a novel treatment for a rare bone disease"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Sirana Pharma collaborates with Pfizer to investigate a novel treatment for a rare bone disease<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]The collaboration aims to identify potential candidates for regenerative repair of diseased muscle and bone tissue using Sirana’s proprietary microRNA (miRNA) targeting approach.[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]June 2022[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”20348″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Sirana Pharma GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Michael Kring, CEO of Sirana Pharma GmbH[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cCombining Sirana\u2019s novel miRNA-targeting approach, and the long-standing experience in musculoskeletal disorders and disease mechanisms of its founders, with the expertise and competencies of Pfizer will allow Sirana to expeditiously evaluate its drug candidates for the treatment of this rare disease and to identify potential candidates for further development.\u201d<\/h6>\n

Michael Kring, CEO of Sirana Pharma GmbH<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Sirana Pharma GmbH, a Martinsried-based biotechnology company focusing on the development of innovative and effective treatments for unmet medical needs in muscle and bone diseases, announced in late June a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease. The collaboration will utilize Sirana\u2019s proprietary microRNA (miRNA)-targeting approach, which targets substantial regenerative recovery of diseased muscle and bone tissue.<\/p>\n

\u201cCombining Sirana\u2019s novel miRNA-targeting approach, and the long-standing experience in musculoskeletal disorders and disease mechanisms of its founders, with the expertise and competencies of Pfizer will allow Sirana to expeditiously evaluate its drug candidates for the treatment of this rare disease and to identify potential candidates for further development,\u201d stated Michael Kring, CEO of Sirana Pharma GmbH.<\/p>\n

\u201cAt Pfizer, we are committed to advancing promising, emerging research \u2013 both through our internal capabilities and through collaborations with companies like Sirana \u2013 with the goal of bringing potentially life-changing medicines to patients around the world,\u201d said Seng H. Cheng, Ph.D., Senior Vice President and Chief Scientific Officer, Pfizer Rare Disease. \u201cWe look forward to working together with the Sirana team to further explore this new and innovative investigational approach, utilizing miRNA-targeting for the potential treatment of rare bone diseases.\u201d<\/p>\n

Sirana Pharma develops therapies for unmet medical needs in musculoskeletal diseases
\n<\/strong>Sirana Pharma GmbH is a privately held biotech company located at the IZB in Martinsried, Germany, which focuses on the development of treatments for unmet medical needs in muscle and bone diseases aimed at restoring musculoskeletal health. Sirana has discovered a novel, innovative mode of action for the treatment of several musculoskeletal disorders and patented a microRNA-targeting approach, which targets substantial regenerative recovery of diseased skeletal muscle and bone tissue. Initially, Sirana focuses on the development of first-in-class molecules to treat Sarcopenia \u2013 age related muscle weakness – and Osteogenesis imperfecta \u2013 inherited brittle bone disease (an orphan drug indication).[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n